News
Patient enrollment finalized in the Phase II trial testing ASC in Sjögren’s syndrome
Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and...
Publication of phase I results of ASC treatment of patients with radiation-induced Xerostomia
The objective of the phase I clinical trial was to evaluate safety and provide proof of concept for efficacy of...
Cell2Cure enters into a collaboration agreement with Endeavour Cells ApS
Cell2Cure has entered into a collaboration agreement with Endeavour Cells ApS, to collaborate on the preparation,...
Cell2Cure enters into a sublicense agreement with Endeavour Cells ApS
Cell2Cure has entered into a sublicense agreement with Endeavour Cells ApS, which will allow Endeavour Cells ApS to...
Collaboration agreement between Cell2Cure and Cbio A/S
Cell2Cure (C2C) has entered into a collaboration agreement with Cbio A/S to establish C2C´s own GMP facility for...
ASC’s enter Phase II testing in Salivary gland re-generation
Patients with head-and neck cancer are often treated with radiation therapy. A side-effect to this life saving therapy...
CSCC´s ASC Heart failure study completed
Heart failure is a serious condition with a high morbidity and mortality. The patient enrolment and 1 year follow-up...
Cell2Cure in a Lung Transplantation study
Lung transplantation is the ultimate treatment of patients with severe lung disease. However, the short- and long-term...
Cell2Cure is part of testing ASC’s to reestablish nerve conduction in the heart
The nerve conduction system within the heart can be destroyed by a process involving increased fibrosis and...
ASC’s enter Phase II testing in Sjögren’s syndrome
Sjögren's syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear...
Cell2Cure partner in a new Stem Cell Center
Cell2Cure, as part of the consortium Clinical Stem cell Innovation and production Center, CSIC, receives funding from...
Publication of phase I trial results – ASC treatment in Sjögren’s syndrome
The clinical phase I study evaluated the safety and feasibility of injecting allogeneic adipose-derived mesenchymal...
CONTACT US
Innobooster grant
SME Instrument grant
This project has received funding from the European Union’s SME Instrument, Horizon 2020 research and innovation programme under grant agreement No [H2020-SMEINST-868284_PRO-SCT]
Grand Solution Grant
Cell2Cure, as part of the consortium Clinical Stem cell Innovation and production Center, CSIC, receives funding from Innovation Fund Denmark.